Member Info for Brighty1

Exactly Billy. 50p is just for starters here. ROAD and MOS have been my stars in 2024 gaining X 10 each but this has X 25 for 2025. Your eventual £2.50 multi billion MCAP prediction could happen. The building blocks being put in place by the GST BOD are very impressive. This is one of those rare shares to hold these days for huge gains....

Good luck, Brighty

Exactly. This is good news and is a standard negotiating win win for both parties involved. If the service provider didn't want to be paid in shares they would just invoice HE1. Interestingly they've opted to take some shares instead which indicates supreme confidence. They won't have done this to be nice! Business is business. Don't forget that this supplier is on the ground / on site & will therefore know much more (than we do) about the feasibility study data / ML and likely success of Itumbula1. All bodes well...

Good luck, Brighty

Exactly and Peter Bardenfleth-Hansen, Christian Eidem and Jochen Rudat are some of the best connected business people in this industry. The Government will want them on side and there's a deal to be done here I'm sure for DGI re UK grants / finance for the company. For those that are unaware Christian Eidem is also particularly well connected, regularly mixing and pictured with the likes of the Trump's, the Murdoch's and Elon Musk (who he was a class mate of). i.e. It's not everyone that gets invited to 10 Downing Street.....

Good luck, Brighty

Hi Yeboha, it's all in the RNS dated 22 November:

* a consolidation of the New Ordinary Shares by 400:1

* every 400 New Ordinary Shares will be consolidated into 1 New Ordinary Share of £0.01 each.

I must admit to feeling rather cynical about the RNS today but not at all surprised. I was actually expecting it.....

Good luck, Brighty

Exactly and there's a previous river tributary that flowed gold where they're located at the Northern Zone, so it's not at all surprising that gold has been discovered at relatively shallow depths where this river flowed. The important aspect though is the reference to high grades of gold. This could be a very valuable discovery indeed.....

Good luck, Brighty

Exactly, that's why I invested in Oracle last month. Timing and due diligence is everything when investing and the real pearl for me was when researching the Northern Zone area I found out about a historical river tributary that flowed gold where they're located. i.e. it's not surprising to me that gold has been discovered at relatively shallow depths where the river flowed. This and the other key messaging, that they had found "significant high grades of gold", was the main driver to invest. What's not to like about that?! I'm happy to hold for the gold....

Good luck, Brighty

Exactly, people are not reading the RNS clearly. The Mineral Resource Estimate (MRE) is coming within days. It's looking very interesting at this price....

Good luck, Brighty

Exactly, the rationale for appearing on Investor Meet is to create investor confidence / awareness not to create uncertainty. Russ could have handled some of those questions much better. Overall a good presentation by Gino and the future does look promising.....

Good luck, Brighty

Exactly and Semnet's not even priced in to the current share price.....

Good luck, Brighty

Exactly. Things are starting to look much more exciting for the company and its shareholders....

Good luck, Brighty

Exactly. The BOD are clearly very optimistic now about revenue generation judging by the language in the RNS today. It's no coincidence that the directors have been buying up cheap GDR shares this year. e.g. FD Russ Shaw bought £25,500, CEO Gino Miele bought £15,000, Chairman Ian Gilham bought £41,000 and Tom Lindsay bought £10,000 GDR shares....

Good luck, Brighty

It was very interesting - from a GS20 Exchange perspective - to note the news that an un-named UK pension scheme had invested in Bitcoin in the last month. The timing is also pertinent. Once the floodgates start to open, Bitcoin especially with President elect Trump being such an advocate, will become increasingly popular . This bodes well for the GS20 exchange.

Background briefing below:

Bitcoin comes to the UK pension sector

An unnamed pension scheme has allocated £1.5m to bitcoin – the first time a UK scheme has invested in the cryptocurrency.

Specialist consultancy Cartwright advised on the allocation, which makes up approximately 3% of the £50m scheme’s investment portfolio.

The allocation is the first of its kind in the UK and took place in October after a rigorous training and due diligence process.

Steve Robinson, head of investment implementation at Cartwright, said: “The operational procedures around this bitcoin investment have been designed to maximise the security of the asset while allowing profits to be taken quickly as and when they arise.

“Our commitment to actively engage with emerging innovative technologies means we can ensure that trustees remain at the cutting edge of investment solutions.

“We are excited to be at the forefront of integrating this exciting asset into a traditionally conservative space and we are confident that this strategic move, coupled with our secure custodial approach, will provide long-term value to scheme members while offering an innovative way to reduce reliance on employer contributions.”

Rather than a traditional structure such as exchange-trade fund (ETFs), Cartwright said the allocation was held directly in “cold storage” – meaning offline – with three institutional custodians. The assets are stored using a multi-signature approach to enhance security".

Who's not looking forward to hearing how the GS20 Exchange has been performing, when we get the results in December. I'm going to be particularly interested in the forward looking statement.....

Good luck, Brighty

Exactly and in addition to the Indian market the Chinese opportunity for Pareta looks very interesting now as well. Some on here will recall the CNIPA patent announcement, which covers Pareta's intellectual property rights in China. It allows the very man, Jochen Rudat, who pioneered Tesla's success in China to do the same for DGI. Whilst Bardenfleth-Hansen and Eidem are capturing most of the attention Rudat played a pivotal role in Tesla’s expansion into China. He spent 10 years working under Elon Musk at Tesla and launched the Models S, 3, X and Roadster in Europe.....

Good luck, Brighty

Exactly, a brilliant update. Pareta India is going to give DGI massive volume in the electric vehicle market, which is projected to exceed US$150 billion by 2030.....

Good luck, Brighty

Exactly, Stay Long - It's why I am invested in DGI. That's a great post by you. Well articulated with top facts. To other posters who've not seen it, the time stamp is 16.02 for part 1 and 16.03 for part 2. DGI is certainly one of the shares I'm most excited about in my portfolio too....

Good luck, Brighty

Exactly, but we are only a week later so far than normal for them to give us notice of the AGM date and venue. It could be that Sareum is waiting on an update re: SRA737. Remember that within 12 months of signature SAR is:

* entitled to a 27.5% share, upon the sooner of 12 months following the signing of the Licensing Agreement,

or

*the event of the Licensee Company achieving certain commercial and material financing objectives.

Those 12 months are very nearly up....

Good luck, Brighty

Just reading through the 72 posts today and I'd recommend a great post at 13.23 today. There's a great line in it: "it only takes one success in life to change many other peoples lives". That sums up perfectly what could happen with QBT, as the post says regarding an Argo Blockchain style rise. Spot on....

Good luck, Brighty

Some interesting posts on here re Lupus over the last 24 hours. For clarity, the global Systemic Lupus Erythematosus (SLE) treatment market is currently valued at around $2.7 billion in 2023. Only two drugs have gained marketing approval specifically for SLE in more than 50 years.

The Lupus marketplace is dominated by GSK’s Benlysta and AstraZeneca’s Saphnelo. These 2 are the only drugs that have gained marketing approval specifically for SLE in over half a century. The overall Lupus treatment market globally is currently dominated by GSK, AstraZeneca, Roche and Aurinia Pharmaceuticals.

This is clearly another great opportunity for Sareum based on what we know from the DOD research.....

Good luck, Brighty

NHS has just released this:

Genetic test developed by Manchester researchers to prevent newborn babies going deaf, to be trialled across the UK

Thursday Nov 21st 2024

A ground-breaking genetic test that could prevent critically ill newborn babies going deaf if treated with gentamicin, a commonly used antibiotic, is being trialled across 14 NHS neonatal (specialist newborn) units across England, Scotland, Wales and Northern Ireland.

Developed by researchers at Saint Mary’s Hospital, part of Manchester University NHS Foundation Trust (MFT) and The University of Manchester, in collaboration with Manchester-based firm genedrive Plc, the rapid bedside test could save the NHS £5 million every year by reducing the need for interventions, such as cochlear implants.

The innovative test was first piloted at Saint Mary’s Hospital and Liverpool Women’s Hospital, in 2020 as part of the Pharmacogenetics to Avoid Loss of Hearing (PALOH) study. Following its success, the test was implemented into routine clinical practice at Saint Mary’s Hospital in 2022 and extended to all three maternity units at MFT, Saint Mary’s Hospital, Wythenshawe Hospital, and North Manchester General Hospital, in 2023.

The National Institute for Health and Care Excellence (NICE) conditionally recommended the genedrive test for use in the NHS last year. It has since been implemented into routine clinical practice at all eight Greater Manchester neonatal units, with funding from Health Innovation Manchester (HInM). So far, the test has prevented the hearing loss of 11 babies at MFT and across Greater Manchester, with 4,000 babies tested to October 2024.

As part of its recommendation, NICE identified areas requiring more information to determine whether the test should be recommended for use at all neonatal sites across the NHS. This includes how the test impacts the time it takes for a baby to be given antibiotics, how the results affect antibiotic prescribing decisions, and the technical performance and accuracy of the test.

Now, having successfully received £1.4m funding from the National Institute for Health and Care Research (NIHR) and the Office for Life Sciences, researchers at MFT will lead PALOH-UK, a new two-year study across 14 neonatal units, from large intensive care units to small special care baby units.

https://research.cmft.nhs.uk/news-events/genetic-test-developed-by-manchester-researchers-to-prevent-newborn-babies-going-deaf-to-be-trialled-across-the-uk

Good luck, Brighty

Thanks. I'm expecting MTEC to keep climbing over the next 12 months on the back of more Government contracts. This 100% gain could be 500%-1000% in due course. The same has happened this year for me with MOS and ROAD, which have both climbed X 8+. It took 12 months to achieve but well worth the wait. Hence why I don't day trade. HE1 and GST are also looking good with excellent gains made in 2024 and hopefully very significant gains to come for these. FWII there's also DGI that could have a healthy re-rate in 2025 onwards too. Anyway, MTEC is still seriously undervalued at 24p when you look at the recent numbers via RNS and the size of contract wins from Government departments.....

Good luck, Brighty